| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -21,217,966 | -16,361,915 |
| Depreciation | 31,666 | 26,885 |
| Amortization of right-of-use asset | 37,731 | 37,731 |
| Share-based compensation expense | 423,563 | 289,239 |
| Change in fair value of warrant liabilities | 9,675,797 | 9,396,636 |
| Prepaid expenses and other current assets | 434,562 | -591,489 |
| Accounts payable and accrued expenses | 259,691 | -1,143,146 |
| Deferred grant income | -25,408 | -25,408 |
| Grants receivable | 198,296 | 176,122 |
| Security deposit | -111,856 | -111,856 |
| Operating lease liability | -38,291 | -38,291 |
| Net cash used in operating activities | -11,374,219 | -7,291,046 |
| Net proceeds from sales of common stock | 8,854,797 | 8,854,797 |
| Payments of deferred offering costs | 455,726 | - |
| Net cash provided by financing activities | 8,399,071 | 8,854,797 |
| Net change in cash | -2,975,148 | 1,563,751 |
| Cash and cash equivalents at beginning of period | 5,811,064 | - |
| Cash and cash equivalents at end of period | 2,835,916 | - |
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)